A Study of OPC-262 in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical study is to evaluate the superiority of the efficacy of OPC-262 (2.5 mg, and 5 mg) to placebo in patients with type 2 diabetes after 24 week treatment in a double-blind fashion and to evaluate the safety of OPC-262 to placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyowa Hakko Kirin Company, Limited; Kyowa Kirin Co., Ltd.

Criteria

Inclusion Criteria:

1. Type 2 diabetes patients with HbA1C above 6.5% and below 10%

2. Patients who are capable of giving informed consent

3. Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the post-observation period)

Exclusion Criteria:

1. Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other specified drugs, mechanisms or diseases, and patients with gestational diabetes mellitus

2. Patients with a medical history of diabetic coma

3. Patients with poorly-controlled hypertension

4. Patients with heart failure

5. Patients with a complication of active hepatitis or hepatic cirrhosis

6. Patients undergoing treatment of glomerular diseases other than diabetic nephropathy

7. Patients with a history or complication of malignant tumor